ClinicalTrials.gg
TerminatedNCT04999605Updated Jan 5, 2024

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

A Phase 1/2 interventional study of AK112 low dose and AK112 medium dose in Ovarian Neoplasms, Recurrent Ovarian Carcinoma and Relapsed Ovarian Cancer, sponsored by Akeso. Terminated at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Too low inclusion rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 392 studies in Ovarian Neoplasms with a site in China — 198 open to participants now, 231 under way, 35 of them phase 3. Ovarian Neoplasms · China.

Enrollment
308th of 319
8 · median 83
Started
2021
with 43 others
Phase 1/2
53 of 392
32 open now
Registered
128th of 392
by date

Among the 392 studies in Ovarian Neoplasms with a site in China, this one is the 308th largest by enrollment of the 319 interventional ones that give a count, is one of 44 that started in 2021, is one of 53 in phase 1/2, and was the 128th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

198 of the 392 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

193 more — sign in →

All 198 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.

03

Conditions studied

  • Ovarian Neoplasms
  • Recurrent Ovarian Carcinoma
  • Relapsed Ovarian Cancer
  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able and willing to provide written .
  • ≥ 18 years old to ≤ 75 years old at study enrollment, female subjects.
  • Have an (ECOG) performance status of 0 or 1.
  • Have a of at least 3 months.
  • Have histologically or cytologically diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  • Have received at least two lines of platinum-containing treatment (bevacizumab or its biosimilars was allowed), and were platinum-sensitive recurrence (progression more than 6 months after the last dose of platinum-containing regimen).
  • Have based on (RECIST) v1.1 assessed by investigator.
  • Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.
  • Has adequate organ function.
  • All subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.
  • Able to to comply with all requirements of study participation (including all study procedures).

Exclusion criteria

Exclusion Criteria:

  • Previous history (within five years) or concurrent malignant neoplasm, except that basal cell carcinoma and/or squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer in situ or breast cancer in situ that has undergone curative therapy.
  • Participation in a study of an drug or using an investigational device within 4 weeks of first study drug administration.
  • Ovarian, fallopian tube or primary peritoneal cancer cancer of non-epithelial origin (such as germ cell carcinoma).
  • Previous targeted therapy using small molecules (except PARP inhibitors) and/or immunotherapy.
  • Have a potent or moderate inhibitor, or a potent or moderate CYP3A inducer within 1 week prior to first study drug administration (or 5 drug half-lives, whichever is longer).
  • Has an active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, or drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Active or previous history of inflammatory bowel disease such as Crohn's disease, ulcerative colitis or chronic diarrhea.
  • History of immunodeficiency and/or antibody positive subjects.
  • Has severe infection 4 weeks prior to first study drug administration, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia; active infection requiring systemic anti-infective therapy within 2 weeks prior to first study drug administration (excluding antiviral therapy for or C).
  • Has known active Hepatitis B that is untreated and requiring antiviral therapy during study period; or active subjects (HCV antibody positive with HCV-RNA levels above the detection threshold).
  • Has undergone major surgery or severe trauma within 30 days prior to the first study drug administration.
  • Has known active central nervous system (CNS) .
  • Uncontrolled co-morbidities including but not limited to symptomatic congestive heart failure (≥2), unstable angina, acute myocardial infarction, poorly controlled arrhythmias, decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe peptic ulcer disease or gastritis.
  • Uncontrolled hypertension despite optimal medical treatment; history of hypertensive crisis or hypertensive encephalopathy.
  • Any arterial thromboembolism, , cerebrovascular accident occurred within 6 months prior to the first study drug administration.
  • History of abdominal fistula or gastrointestinal perforation associated with anti-VEGF therapy; imaging results revealed invasion of the intestinal wall by tumor during screening.
  • Imaging or clinical findings of gastrointestinal obstruction, including incomplete obstruction.
  • Unable to swallow tablets or has had gastrointestinal abnormalities that may affect drug absorption as determined by the investigator.
  • Has had within 30 days prior to first study drug administration or plan to receive live vaccine during the study period.
  • Has known psychiatric or substance abuse disorders, including alcohol or drug abuse.
  • Pregnant or lactating female subject.
  • Any prior or concurrent disease, treatment, or laboratory test abnormality that may confuse study results, affect subjects' full participation in the study, or may not be in their best interest to participate.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AK112

    AK112 injection

    Drug: AK112 low dose · Drug: AK112 medium dose · Drug: AK112 high dose

Interventions

  • AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor

  • AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor

  • AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor

This study also gives Olaparib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Safety endpoint: number of subjects with adverse events (AE)

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 years

  2. Primary efficacy endpoint: objective response rate (ORR)

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) assessed according to RECIST v1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Efficacy Endpoint assessed according to RECIST v1.1 : disease control rate (DCR)

    DCR based on RECIST v1.1. DCR is defined as the proportion of subjects with CR, PR, or SD.

    Time frame: Up to approximately 2 years

  2. Efficacy Endpoint assessed according to RECIST v1.1 : progression-free survival (PFS)

    PFS based on RECIST v1.1. PFS is defined as the time from the date of randomization till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first)

    Time frame: Up to approximately 2 years

  3. Efficacy Endpoint assessed according to RECIST v1.1 : Overall survival (OS)

    OS based on RECIST v1.1. OS is defined as the time from the date of randomization or first dosing date to death due to any cause

    Time frame: Up to approximately 2 years

  4. Serum PK concentrations of AK112

    Serum PK concentrations of AK112 in individual subjects at different time points after AK112 administration

    Time frame: Up to approximately 2 years

  5. To evaluate the immunogenicity of AK112: Number of subjects with anti-drug antibodies (ADA)

    Immunogenicity of AK112: Number of subjects with detectable anti-drug antibodies (ADA)

    Time frame: Up to approximately 2 years

  6. To evaluate the immunogenicity of AK112: Percentage of subjects with anti-drug antibodies (ADA)

    Immunogenicity of AK112: Percentage of subjects with detectable anti-drug antibodies (ADA)

    Time frame: Up to approximately 2 years

  7. To evaluate the correlation between the expression of PD-L1 and the antitumor activity of AK112 in tumor tissues

    Correlation between PD-L1 and AK112 in tumor tissues

    Time frame: Up to approximately 2 years

  8. To evaluate the association between gBRCA1/2 mutation in peripheral blood and the antitumor activity of AK112 in subjects with recurrent ovarian cancer

    Association between gBRCA1/2 mutation in peripheral blood and antitumor activity of AK112

    Time frame: Up to approximately 2 years

07

Study locations

1 site
  • Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jun 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
Aug 11, 2021
StartActual
Jun 24, 2021
Primary completionActual
Jun 10, 2022
CompletionActual
Jun 10, 2022
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04999605
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Aug 11, 2021
Start date
Jun 24, 2021
Primary completion
Jun 10, 2022
Completion
Jun 10, 2022
Last update
Jan 5, 2024

Study contacts

Lingying Wu, MD
principal investigator · Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion